Here, we present the first observation of a smectic B (Sm(B)) phase in a system of charged colloidal gibbsite platelets suspended in dimethyl sulfoxide (DMSO). The use of DMSO, a polar aprotic solvent, leads to a long range of the electrostatic Coulomb repulsion between platelets. We believe this to be responsible for the formation of the layered liquid crystalline phase consisting of hexagonally ordered particles, that is, the Sm(B) phase. We support our finding by high-resolution X-ray scattering experiments, which additionally indicate a high degree of ordering in the Sm(B) phase.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/ja300527w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
To explore whether ultra-sensitive circulating tumor DNA (ctDNA) profiling enables early prediction of treatment response and early detection of disease progression, we applied NeXT Personal, an ultra-sensitive bespoke tumor-informed liquid biopsy platform, to profile tumor samples from the KeyLargo study, a phase II trial in which metastatic esophagogastric cancer (mEGC) patients received capecitabine, oxaliplatin, and pembrolizumab. All 25 patients evaluated were ctDNA-positive at baseline. Minimal residual disease (MRD) events varied from 406,067 down to 1.
View Article and Find Full Text PDFFatigue-induced changes in electromyographic activity after repeated racing turns: a pilot study.
Eur J Appl Physiol
December 2024
Inter-university Laboratory of Human Movement Sciences, Univ. Savoie Mont Blanc, EA 7424, 73000, Chambéry, France.
Purpose: Alpine skiing races are physically demanding events characterized by numerous repeated near-maximal activations of the lower limb muscles. Although this type of task is known to induce neuromuscular fatigue, electromyographic activity (EMG) adaptations after repeated maximal-intensity skiing have not been previously investigated.
Methods: Six skiers completed a 6-turns section with (FAT) and without performing 30 giant slalom (GS) turns (CONT).
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
Lancet
December 2024
Dr Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Mirikizumab, a humanised monoclonal antibody that inhibits IL-23p19, is effective in moderate-to-severe ulcerative colitis. We aimed to evaluate the efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease.
Methods: VIVID-1 was a global phase 3, randomised, double-blind, double-dummy, placebo-controlled and active-controlled, treat-through study.
Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial.
Nat Commun
November 2024
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, USA.
Article Synopsis
- * In a Phase II clinical trial, 27 patients received entinostat followed by nivolumab, resulting in an objective response rate of 11% and a median response duration of over 10 months, although the primary endpoint for overall effectiveness was not reached.
- * The combination treatment led to significant immune profile changes, including increased dendritic cell activity and enhanced inflammatory response, suggesting potential for improving treatment strategies in PDA despite
Dissociation of White Matter Bundles in Different Recovery Measures in Poststroke Aphasia.
Stroke
November 2024
École d'orthophonie et d'audiologie (A.O.G., A.B., K.M), Université de Montréal, Quebec, Canada.
Background: Poststroke aphasia (PSA) recovery shows high variability across individuals and at different time points. Although diffusion biomarkers from the ventral and dorsal streams have demonstrated strong predictive power for language outcomes, it is still unclear how these biomarkers relate to the various stages of PSA recovery. In this study, we aim to compare diffusion metrics and language measures as predictors of language recovery in a longitudinal cohort of participants with PSA.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!